vs
亚盛医药集团（AAPG）与百特国际（BAX）财务数据对比。点击上方公司名可切换其他公司
百特国际的季度营收约是亚盛医药集团的5180.1倍（$3.0B vs $574.1K）
亚盛医药集团是一家全球性临床阶段生物技术企业，专注于开发用于治疗癌症、慢性病毒感染及衰老相关疾病的创新靶向药物，核心研发方向为靶向细胞凋亡通路的小分子药物，业务覆盖中、美等全球市场，致力于满足未被满足的临床需求。
百特国际是总部位于美国伊利诺伊州迪尔菲尔德的跨国医疗健康企业，业务布局覆盖全球众多市场，专注于研发、生产及销售各类医疗相关产品与解决方案，为全球医疗机构和患者提供专业可靠的医疗支持。
AAPG vs BAX — 直观对比
营收规模更大
BAX
是对方的5180.1倍
$574.1K
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $574.1K | $3.0B |
| 净利润 | — | $-1.1B |
| 毛利率 | — | 19.4% |
| 营业利润率 | — | -24.5% |
| 净利率 | — | -37.9% |
| 营收同比 | — | 458.0% |
| 净利润同比 | — | -120.3% |
| 每股收益（稀释后） | — | $-2.21 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AAPGBAX
| Q4 25 | $574.1K | $3.0B | ||
| Q3 25 | — | $2.8B | ||
| Q2 25 | $32.6M | $2.8B | ||
| Q1 25 | — | $2.6B | ||
| Q4 24 | — | $533.0M | ||
| Q3 24 | — | $2.7B | ||
| Q2 24 | — | $3.8B | ||
| Q1 24 | — | $3.6B |
净利润AAPGBAX
| Q4 25 | — | $-1.1B | ||
| Q3 25 | — | $-46.0M | ||
| Q2 25 | $11.4M | $91.0M | ||
| Q1 25 | — | $126.0M | ||
| Q4 24 | — | $-512.0M | ||
| Q3 24 | — | $140.0M | ||
| Q2 24 | — | $-314.0M | ||
| Q1 24 | — | $37.0M |
毛利率AAPGBAX
| Q4 25 | — | 19.4% | ||
| Q3 25 | — | 33.5% | ||
| Q2 25 | 90.7% | 35.3% | ||
| Q1 25 | — | 32.8% | ||
| Q4 24 | — | 25.0% | ||
| Q3 24 | — | 38.3% | ||
| Q2 24 | — | 37.5% | ||
| Q1 24 | — | 38.6% |
营业利润率AAPGBAX
| Q4 25 | — | -24.5% | ||
| Q3 25 | — | 6.1% | ||
| Q2 25 | — | 6.8% | ||
| Q1 25 | — | 2.2% | ||
| Q4 24 | — | -25.5% | ||
| Q3 24 | — | 5.7% | ||
| Q2 24 | — | -5.0% | ||
| Q1 24 | — | 5.2% |
净利率AAPGBAX
| Q4 25 | — | -37.9% | ||
| Q3 25 | — | -1.6% | ||
| Q2 25 | — | 3.2% | ||
| Q1 25 | — | 4.8% | ||
| Q4 24 | — | -96.1% | ||
| Q3 24 | — | 5.2% | ||
| Q2 24 | — | -8.2% | ||
| Q1 24 | — | 1.0% |
每股收益（稀释后）AAPGBAX
| Q4 25 | — | $-2.21 | ||
| Q3 25 | — | $-0.09 | ||
| Q2 25 | — | $0.18 | ||
| Q1 25 | — | $0.25 | ||
| Q4 24 | — | $-0.99 | ||
| Q3 24 | — | $0.27 | ||
| Q2 24 | — | $-0.62 | ||
| Q1 24 | — | $0.07 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $2.0B |
| 总债务越低越好 | — | $9.5B |
| 股东权益账面价值 | — | $6.1B |
| 总资产 | — | $20.1B |
| 负债/权益比越低杠杆越低 | — | 1.55× |
8季度趋势，按日历期对齐
现金及短期投资AAPGBAX
| Q4 25 | — | $2.0B | ||
| Q3 25 | — | $1.7B | ||
| Q2 25 | — | $1.7B | ||
| Q1 25 | — | $2.3B | ||
| Q4 24 | — | $1.8B | ||
| Q3 24 | — | $1.4B | ||
| Q2 24 | — | $2.1B | ||
| Q1 24 | — | $3.0B |
总债务AAPGBAX
| Q4 25 | — | $9.5B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $10.4B | ||
| Q3 24 | — | $10.4B | ||
| Q2 24 | — | $10.4B | ||
| Q1 24 | — | $11.1B |
股东权益AAPGBAX
| Q4 25 | — | $6.1B | ||
| Q3 25 | — | $7.2B | ||
| Q2 25 | — | $7.3B | ||
| Q1 25 | — | $7.1B | ||
| Q4 24 | — | $7.0B | ||
| Q3 24 | — | $7.9B | ||
| Q2 24 | — | $7.6B | ||
| Q1 24 | — | $8.2B |
总资产AAPGBAX
| Q4 25 | — | $20.1B | ||
| Q3 25 | — | $21.1B | ||
| Q2 25 | — | $21.0B | ||
| Q1 25 | — | $21.3B | ||
| Q4 24 | — | $25.8B | ||
| Q3 24 | — | $26.7B | ||
| Q2 24 | — | $26.3B | ||
| Q1 24 | — | $27.8B |
负债/权益比AAPGBAX
| Q4 25 | — | 1.55× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.49× | ||
| Q3 24 | — | 1.33× | ||
| Q2 24 | — | 1.37× | ||
| Q1 24 | — | 1.36× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $584.0M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流AAPGBAX
| Q4 25 | — | $584.0M | ||
| Q3 25 | — | $237.0M | ||
| Q2 25 | — | $217.0M | ||
| Q1 25 | — | $-193.0M | ||
| Q4 24 | — | $488.0M | ||
| Q3 24 | — | $253.0M | ||
| Q2 24 | — | $115.0M | ||
| Q1 24 | — | $163.0M |
现金转化率AAPGBAX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 2.38× | ||
| Q1 25 | — | -1.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.81× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 4.41× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AAPG
暂无分部数据
BAX
| Other | $1.5B | 51% |
| Infusion Therapies And Technologies | $543.0M | 18% |
| Pharmaceutical Compounding | $316.0M | 11% |
| Front Line Care | $219.0M | 7% |
| Injectables And Anesthesia | $190.0M | 6% |
| Advanced Surgery | $177.0M | 6% |
